Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q3 2025. This comprehensive report uses industry-leading data from Biomedtracker, aiding informed decisions about drug pipeline prioritization, partnerships, acquisitions, and drug approval data. Submit the form to download the complete outlook report and discover the insights and predictions that will shape Q3.
Share:
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q3 2025.
This comprehensive report uses industry-leading data from Biomedtracker, aiding informed decisions about drug pipeline prioritization, partnerships, acquisitions, and drug approval data.
Submit the form to download the complete outlook report and discover the insights and predictions that will shape Q3.
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
